Concepedia

Author

Heike Horn

Robert Bosch HospitalORCID

Also Known As

H D HORN, H D Horn, H Horn, H. -D. Horn, H. D. Horn, H. HORN, H. Horn, H.-D. Horn, H.D. Horn, Heike Horn

129

Publications

6.4K

Citations

34

H-Index

52

Concepts

All Affiliations

Robert Bosch HospitalDr. Margarete Fischer-Bosch-Institute of Clinical PharmacologyUniversity of WürzburgUniversity of TübingenComprehensive Cancer Center Mainfranken
HH

About

Heike Horn is an author at Robert Bosch Hospital specializing in medicine, pathology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

18

3.2K

2

Cell Biology

6

6

2.1K

3

Engineering

3

3

70

4

Health Sciences

2

2

94

5

Biomedical Engineering

1

1

25

Heike Horn

×

46

Publications

5.8K

Citations

30

H-Index

YearCitations

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy, Chip Stewart, Andrew Dunford,

Nature Medicine

2018

1.9K

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Alessandro Pastore, Vindi Jurinović, Robert Kridel,

The Lancet Oncology

2015

608

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

Heike Horn, Marita Ziepert, Claudia Becher,

Blood

2013

540

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology

David W. Scott, Rebecca L. King, Annette M. Staiger,

Blood

2018

236

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Vindi Jurinović, Robert Kridel, Annette M. Staiger,

Blood

2016

226

Clinical Impact of the Cell-of-Origin Classification and the <i>MYC</i> / <i>BCL2</i> Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group

Annette M. Staiger, Marita Ziepert, Heike Horn,

Journal of Clinical Oncology

2017

214

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL

German Ott, Marita Ziepert, Wolfram Klapper,

Blood

2010

200

Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL

Anja Schmitt, Wendan Xu, Philip Bucher,

Blood

2021

176

Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles

Heike Horn, Carsten Schmelter, Ellen Leich,

Haematologica

2011

166

The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma

Dido Lenze, Lorenzo Leoncini, Michael Hummel,

Leukemia

2011

123

Page 1